Therapeutic implications of targeting energy metabolism in breast cancer

PPAR Research

Volumn , Issue , 2013, Pages

  Sakharkar, Meena K ^a   Shashni, Babita ^a   Sharma, Karun ^a   Dhillon, Sarinder K ^b   Ranjekar, Prabhakar R ^c   Sakharkar, Kishore R ^d,e  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c BHARATI VIDYAPEETH UNIVERSITY   (India)

^d NONE

^e Bharati Vidyapeeth Deemed University   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 PHOSPHOFRUCTO 2 KINASE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRUCTOSE 2,6 BISPHOSPHATASE; GLUCOSE; HEXOKINASE; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SODIUM PROTON EXCHANGE PROTEIN 1; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; BREAST CANCER; DIABETES MELLITUS; ENERGY METABOLISM; GLYCOLYSIS; GLYCOSYLATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NEOPLASM; OBESITY; PH; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SCHIZOPHRENIA; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84874629561     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/109285     Document Type: Review

References (112)

1. Kota B. P., Huang T. H., Roufogalis B. D., An overview on biological mechanisms of PPARs. Pharmacological Research 2005 51 2 85 94 10.1016/j.phrs.2004.07.012 (Pubitemid 40040538)
2. Tous M., Ferré N., Rull A., Marsillach J., Coll B., Alonso-Villaverde C., Camps J., Joven J., Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochemical and Biophysical Research Communications 2006 340 4 1078 1084 2-s2.0-30544434288 10.1016/j.bbrc.2005.12.109 (Pubitemid 43083388)
3. Castelein H., Gulick T., Declercq P. E., Mannaerts G. P., Moore D. D., Baes M. I., The peroxisome proliferator activated receptor regulates malic enzyme gene expression. The Journal of Biological Chemistry 1994 269 43 26754 26758 2-s2.0-0028029797 (Pubitemid 24332868)
4. van Bilsen M., van der Vusse G. J., Gilde A. J., Lindhout M., van der Lee K. A. J. M., Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression. Molecular and Cellular Biochemistry 2002 239 1-2 131 138 2-s2.0-0036813001 10.1023/A:1020553428294 (Pubitemid 35385804)
5. Mansure J. J., Nassim R., Kassouf W., Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target in cancer. Cellular and Genetic Practices for Translational Medicine 2011 8 7 Research Signpost 169 195
6. Park J. I., The role of 15d-PGJ2, a natural ligand for peroxisome proliferator-activated receptor γ (PPAR γ), in cancer. Pharmacological Research 2005 51 2 85 94
7. Woo C. C., Loo S. Y., Gee V., Yap C. W., Sethi G., Kumar A. P., Benny Tan K. H., Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR- γ pathway. Biochemical Pharmacology 2011 82 5 464 475 2-s2.0-79960929095 10.1016/j.bcp.2011.05.030
8. Lu Y. L., Li G. L., Huang H. L., Zhong J., Dai L. C., Peroxisome proliferator-activated receptor- γ 34C > G polymorphism and colorectal cancer risk: a meta-analysis. World Journal of Gastroenterology 2010 16 17 2170 2175 2-s2.0-77952513134 10.3748/wjg.v16.i17.2170
9. Venkatachalam G., Kumar A. P., Yue L. S., Pervaiz S., Clement M. V., Sakharkar M. K., Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human. BMC Genomics 2009 10 supplement 3, article S5 2-s2.0-71549131007
10. Jeong Y., Xie Y., Lee W., Bookout A. L., Girard L., Raso G., Behrens C., Wistuba I. I., Gadzar A. F., Minna J. D., Mangelsdorf D. J., Research resource: diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Molecular Endocrinology 2012 26 8 1443 1454 10.1210/me.2011-1382
11. Kip1 in human pancreatic carcinoma cells. Cancer Research 2000 60 19 5558 5564 2-s2.0-0034306992
12. Govindarajan R., Ratnasinghe L., Simmons D. L., Siegel E. R., Midathada M. V., Kim L., Kim P. J., Owens R. J., Lang N. P., Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. Journal of Clinical Oncology 2007 25 12 1476 1481 2-s2.0-34248192254 10.1200/JCO.2006.07. 2777 (Pubitemid 46733074)
13. Yu H. N., Lee Y. R., Noh E. M., Lee K. S., Kim J. S., Song E. K., Han M. K., Lee Y. C., Kwon K. B., Lee S. J., Youn H. J., Jung S. H., Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPAR γ) ligand. Cell Biology International 2008 32 8 906 912 2-s2.0-47349108152 10.1016/j.cellbi.2008.04.011
14. Bonofiglio D., Aquila S., Catalano S., Gabriele S., Belmonte M., Middea E., Qi H., Morelli C., Gentile M., Maggiolini M., Andò S., Peroxisome proliferator-activated receptor- γ activates p53 gene promoter binding to the nuclear factor- B sequence in human MCF7 breast cancer cells. Molecular Endocrinology 2006 20 12 3083 3092 2-s2.0-33751517072 10.1210/me.2006-0192 (Pubitemid 44833557)
15. Pignatelli M., Cocca C., Santos A., Perez-Castillo A., Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line. Oncogene 2003 22 35 5446 5450 2-s2.0-0042335764 10.1038/sj.onc.1206824 (Pubitemid 37072199)
16. Rubin G. L., Zhao Y., Kalus A. M., Simpson E. R., Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Research 2000 60 6 1604 1608 2-s2.0-0034654120 (Pubitemid 30183431)
17. Turturro F., Friday E., Fowler R., Surie D., Welbourne T., Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator- activated receptor γ -independent mechanism in breast cancer-derived cell lines. Clinical Cancer Research 2004 10 20 7022 7030 2-s2.0-6044243631 10.1158/1078-0432.CCR-04-0879 (Pubitemid 39383054)
18. Smith A. G., Muscat G. E., Orphan nuclear receptors: therapeutic opportunities in skeletal muscle. American Journal of Physiology 2006 291 2 C203 C217 10.1152/ajpcell.00476.2005 (Pubitemid 44148142)
19. Mukhopadhyay S., Das S. K., Mukherjee S., Expression of Mn-superoxide dismutase gene in nontumorigenic and tumorigenic human mammary epithelial cells. Journal of Biomedicine and Biotechnology 2004 2004 4 195 202 2-s2.0-12344255776 10.1155/S1110724304401016 (Pubitemid 40128955)
20. Fedele P., Calvani N., Marino A., Orlando L., Schiavone P., Quaranta A., Cinieri S., Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Critical Reviews in Oncology/Hematology 2012 51 2 85 94
21. Seyfried T. N., Shelton L. M., Cancer as a metabolic disease. Nutrition & Metabolism 2010 7, article 7 10.1186/1743-7075-7-7
22. Klement R. J., Kämmerer U., Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutrition & Metabolism 2011 8, article 75 10.1186/1743-7075-8-75
23. Bi X., Lin Q., Foo T. W., Joshi S., You T., Shen H. M., Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Molecular & Cellular Proteomics 2006 5 1119 1130 10.1074/mcp.M500432-MCP200 (Pubitemid 43985935)
24. Unwin R. D., Craven R. A., Harnden P., Hanrahan S., Totty N., Knowles M., Eardley I., Selby P. J., Banks R. E., Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003 3 8 1620 1632 2-s2.0-0042861598 10.1002/pmic.200300464 (Pubitemid 37048086)
25. Perroud B., Lee J., Valkova N., Dhirapong A., Lin P. Y., Fiehn O., Kültz D., Weiss R. H., Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer 2006 5, article 64 2-s2.0-33845631556 10.1186/1476-4598-5-64 (Pubitemid 44941442)
26. Isidoro A., Casado E., Redondo A., Acebo P., Espinosa E., Alonso A. M., Cejas P., Hardisson D., Fresno Vara J. A., Belda-Iniesta C., González-Barón M., Cuezva J. M., Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005 26 12 2095 2104 2-s2.0-27944502154 10.1093/carcin/bgi188 (Pubitemid 41672197)
27. + breast cancer. Cancer Research 2012 72 8 1935 1942 10.1158/0008-5472.CAN-11-3266
28. de Oliveira M. F., Amoêdo N. D., Rumjanek F. D., Energy and redox homeostasis in tumor cells. International Journal of Cell Biology 2012 2012 15 593838 10.1155/2012/593838
29. Ward P. S., Thompson C. B., Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012 21 3 297 308 10.1016/j.ccr.2012.02.014
30. Mentis A. F. A., Kararizou E., Metabolism and cancer: an up-to-date review of a mutual connection. Asian Pacific Journal of Cancer Prevention 2010 11 6 1437 1444 2-s2.0-79956123670
31. Zha X., Sun Q., Zhang H., mTOR upregulation of glycolytic enzymes promotes tumor development. Cell Cycle 2011 10 7 1015 1016 2-s2.0-79953650247 10.4161/cc.10.7.15063
32. Menendez J. A., Vellon L., Oliveras-Ferraros C., Cufí S., Vazquez-Martin A., mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011 10 21 3658 3677 10.4161/cc.10.21.18128
33. Williams A. C., Collard T. J., Paraskeva C., An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999 18 21 3199 3204 2-s2.0-0033609365 10.1038/sj.onc.1202660 (Pubitemid 29286964)
34. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A. K., Frank P. G., Casimiro M. C., Wang C., Fortina P., Addya S., Pestell R. G., Martinez-Outschoorn U. E., Sotgia F., Lisanti M. P., The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009 8 23 3984 4001 2-s2.0-74849087878
35. Guppy M., Leedman P., Zu X., Russell V., Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochemical Journal 2002 364, part 1 309 315 2-s2.0-0037093411 (Pubitemid 34538975)
36. Gatenby R. A., Gawlinski E. T., Gmitro A. F., Kaylor B., Gillies R. J., Acid-mediated tumor invasion: a multidisciplinary study. Cancer Research 2006 66 10 5216 5223 2-s2.0-33744942376 10.1158/0008-5472.CAN-05-4193 (Pubitemid 43844945)
37. Homem de Bittencourt P. I. Jr., Peres C. M., Yano M. M., Hirata M. H., Curi R., Pyruvate is a lipid precursor for rat lymphocytes in culture: evidence for a lipid exporting capacity. Biochemistry and Molecular Biology International 1993 30 4 631 641 2-s2.0-0027203898 (Pubitemid 23250506)
38. Kondoh H., Lleonart M. E., Bernard D., Gil J., Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histology and Histopathology 2007 22 1 85 90 2-s2.0-33846324730 (Pubitemid 46117093)
39. Gatenby R. A., Gillies R. J., Why do cancers have high aerobic glycolysis? Nature Reviews Cancer 2004 4 11 891 899 2-s2.0-8144228566 10.1038/nrc1478 (Pubitemid 39472955)
40. Gillies R. J., Gatenby R. A., Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? Journal of Bioenergetics and Biomembranes 2007 39 3 251 257 2-s2.0-35448940364 10.1007/s10863-007-9085-y (Pubitemid 47619378)
41. Biamonti G., Caceres J. F., Cellular stress and RNA splicing. Trends in Biochemical Sciences 2009 34 3 146 153 2-s2.0-62849087517 10.1016/j.tibs.2008. 11.004
42. Greijer A. E., van der Groep P., Kemming D., Shvarts A., Semenza G. L., Meijer G. A., van de Wiel M. A., Belien J. A. M., van Diest P. J., van der Wall E., Up-regualtion of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor I (HIF-I). Journal of Pathology 2005 206 3 291 304 2-s2.0-21344438419 10.1002/path.1778 (Pubitemid 40903193)
43. Serkova N., Boros L. G., Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. American Journal of PharmacoGenomics 2005 5 5 293 302 2-s2.0-26444469502 10.2165/00129785-200505050- 00002 (Pubitemid 41425607)
44. Hsu P., Sabatini D., Cancer cell metabolism: Warburg and beyond. Cell 2008 134 5 703 707 10.1016/j.cell.2008.08.021
45. Dhahbi J., Kim H., Mote P., Beaver R., Spindler S., Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proceedings of the National Academy of Sciences of the United States of America 2004 101 15 5524 5529 10.1073/pnas.0305300101 (Pubitemid 38481190)
46. Lunt S. Y., Vander Heiden M. G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual Review of Cell and Developmental Biology 2011 27 441 464 10.1146/annurev-cellbio-092910-154237
47. John S., Weiss J. N., Ribalet B., Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS ONE 2011 6 3 2-s2.0-79952417296 10.1371/journal.pone.0017674 e17674
48. Mathupala S. P., Ko Y. H., Pedersen P. L., Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Seminars in Cancer Biology 2009 19 1 17 24 2-s2.0-60249083822 10.1016/j.semcancer.2008.11.006
49. Mathupala S. P., Ko Y. H., Pedersen P. L., Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006 25 34 4777 4786 2-s2.0-33746924468 10.1038/sj.onc.1209603 (Pubitemid 44187625)
50. Mendoza E. E., Pocceschi M. G., Kong X., Leeper D. B., Caro J., Limesand K. H., Burd R., Control of glycolytic flux by AMP-activated protein kinase in tumor cells adapted to low pH. Translational Oncology 2012 5 3 208 216
51. Ferguson E. C., Rathmell J. C., New roles for pyruvate kinase M2: working out the Warburg effect. Trends in Biochemical Sciences 2008 33 8 359 362 2-s2.0-48149114282 10.1016/j.tibs.2008.05.006
52. David C. J., Chen M., Assanah M., Canoll P., Manley J. L., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010 463 7279 364 368 2-s2.0-75149150660 10.1038/nature08697
53. Shashni B., Sakharkar K. R., Nagasaki Y., Sakharkar M. K., Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPAR gamma in breast cancer pathophysiology. Journal of Drug Targeting. In press
54. Venkatachalam G., Kumar A. P., Sakharkar K. R., Thangavel S., Clement M. V., Sakharkar M. K., PPAR γ disease gene network and identification of therapeutic targets for prostate cancer. Journal of Drug Targeting 2011 19 9 781 796 10.3109/1061186X.2011.568062
55. Lagana A., Vadnais J., Le P. U., Nguyen T. N., Laprade R., Nabi I. R., Noel J., Regulation of the formation of tumor cell pseudopodia by the Na(+)/H(+) exchanger NHE1. Journal of Cell Science 2000 113, part 20 3649 3662 2-s2.0-0033739497
56. + exchanger, NHE1: structure, regulation, and cellular actions. Annual Review of Pharmacology and Toxicology 2002 42 527 552 2-s2.0-0036174658 10.1146/annurev.pharmtox.42.092001.143801 (Pubitemid 34160535)
57. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. The FASEB Journal 2000 14 14 2185 2197 2-s2.0-0033746761
58. Grinstein S., Dixon S. J., Ion transport, membrane potential, and cytoplasmic pH in lymphocytes: changes during activation. Physiological Reviews 1989 69 2 417 481 2-s2.0-0024604424 (Pubitemid 19101666)
59. Bell S. M., Schreiner S. M., Schultheis P. J., Targeted disruption of the murine NHE1 locus induces ataxia, growth retardation, and seizures. American Journal of Physiology 1999 276 C788 C795 (Pubitemid 29211306)
60. Pouyssegur J., Franchi A., Pages G., pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Foundation Symposium 2001 240 186 196 (Pubitemid 33603787)
61. Turturro F., Friday E., Fowler R., Surie D., Welbourne T., Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator- activated receptor γ -independent mechanism in breast cancer-derived cell lines. Clinical Cancer Research 2004 10 20 7022 7030 2-s2.0-6044243631 10.1158/1078-0432.CCR-04-0879 (Pubitemid 39383054)
62. + exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. Cell Death and Differentiation 2006 13 4 628 641 2-s2.0-33644936885 10.1038/sj.cdd.4401775
63. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995 83 5 813 819 2-s2.0-0028972026 (Pubitemid 3006325)
64. Pelicano H., Carney D., Huang P., ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates 2004 7 2 97 110 2-s2.0-2942593991 10.1016/j.drup.2004.01.004 (Pubitemid 38736063)
65. Gibellini L., Pinti M., Nasi M., de Biasi S., Roat E., Bertoncelli L., Cossarizza A., Interfering with ROS metabolism in cancer cells: the potential role of quercetin. Cancers 2010 2 2 1288 1311 2-s2.0-79952265034 10.3390/cancers2021288
66. Storey K. B., Oxidative stress: animal adaptations in nature. Brazilian Journal of Medical and Biological Research 1996 29 12 1715 1733 (Pubitemid 126485423)
67. Janssen A. M. L., Bosman C. B., van Duijn W., Oostendorp-van de Ruit M. M., Kubben F. J. G. M., Griffioen G., Lamers C. B. H. W., van Krieken J. H. J. M., van de Velde C. J. H., Verspaget H. W., Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clinical Cancer Research 2000 6 8 3183 3192 2-s2.0-0033900975 (Pubitemid 30637746)
68. Kanbagli O., Ozdemirler G., Bulut T., Yamaner S., Aykaç-Toker G., Uysal M., Mitochondrial lipid peroxides and antioxidant enzymes in colorectal adenocarcinoma tissues. Japanese Journal of Cancer Research 2000 91 12 1258 1263 (Pubitemid 32042360)
69. Punnonen K., Ahotupa M., Asaishi K., Hyöty M., Kudo R., Punnonen R., Antioxidant enzyme activities and oxidative stress in human breast cancer. Journal of Cancer Research and Clinical Oncology 1994 120 6 374 377 2-s2.0-0028210850 (Pubitemid 24101438)
70. Cobbs C. S., Levi D. S., Aldape K., Israel M. A., Manganese superoxide dismutase expression in human central nervous system tumors. Cancer Research 1996 56 14 3192 3195 2-s2.0-0029902072 (Pubitemid 26242959)
71. Hileman E. A., Achanta G., Huang P., Superoxide dismutase: an emerging target for cancer therapeutics. Expert Opinion on Therapeutic Targets 2001 5 6 697 710 2-s2.0-33748518966 (Pubitemid 33781100)
72. Nishiura T., Suzuki K., Kawaguchi T., Nakao H., Kawamura, Taniguchi M., Kanayama Y., Yonezawa T., Iizuka S., Taniguchi N., Elevated serum manganese superoxide dismutase in acute leukemias. Cancer Letters 1992 62 3 211 215 2-s2.0-0026525295 10.1016/0304-3835(92)90098-G
73. Senthil S., Veerappan R. M., Ramakrishna Rao M., Pugalendi K. V., Oxidative stress and antioxidants in patients with cardiogenic shock complicating acute myocardial infarction. Clinica Chimica Acta 2004 348 1-2 131 137 2-s2.0-4444226990 10.1016/j.cccn.2004.05.004 (Pubitemid 39209011)
74. Weisberg S. P., McCann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 2003 112 12 1796 1808 2-s2.0-0348230958 10.1172/JCI200319246 (Pubitemid 38063703)
75. Hajer G. R., van Haeften T. W., Visseren F. L., Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European Heart Journal 2008 29 24 2959 2971 10.1093/eurheartj/ehn387
76. Kumar-Sinha C., Ignatoski K. W., Lippman M. E., Ethier S. P., Chinnaiyan A. M., Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Research 2003 63 1 132 139 2-s2.0-0037226462 (Pubitemid 36070431)
77. Menendez J. A., Mehmi I., Verma V. A., Teng P. K., Lupu R., Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Molecular Carcinogenesis 2004 41 3 164 178 2-s2.0-7244252915 10.1002/mc.20054 (Pubitemid 39435113)
78. Menendez J. A., Oza B. P., Atlas E., Verma V. A., Mehmi I., Lupu R., Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene 2004 23 28 4945 4958 2-s2.0-3042723614 10.1038/sj.onc.1207476 (Pubitemid 38932167)
79. Hardy S., Langelier Y., Prentki M., Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Research 2000 60 22 6353 6358 2-s2.0-0033692758
80. Hardy S., El-Assaad W., Przybytkowski E., Joly E., Prentki M., Langelier Y., Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. The Journal of Biological Chemistry 2003 278 34 31861 31870 2-s2.0-0041355315 10.1074/jbc.M300190200 (Pubitemid 37048370)
81. Desvergne B., Wahli W., Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 649 688 10.1210/er.20.5.649 (Pubitemid 30650602)
82. Medina-Gomez G., Gray S., Vidal-Puig A., Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor γ (PPAR γ) and PPAR γ coactivator-1 (PGC1). Public Health Nutrition 2007 10 10 1132 1137 2-s2.0-36048950218 10.1017/S1368980007000614 (Pubitemid 350085201)
83. Han L., Zhou R., Niu J., McNutt M. A., Wang P., Tong T., SIRT1 is regulated by a PPAR γ -SIRT1 negative feedback loop associated with senescence. Nucleic Acids Research 2010 38 21 7458 7471
84. Giovannucci E., Harlan D. M., Archer M. C., Bergenstal R. M., Gapstur S. M., Habel L. A., Pollak M., Regensteiner J. G., Yee D., Diabetes and cancer: a consensus report. CA Cancer Journal for Clinicians 2010 60 4 207 221 2-s2.0-77953846828 10.3322/caac.20078
85. Liao S., Li J., Wang L., Zhang Y., Wang C., Type 2 diabetes mellitus and characteristics of breast cancer in China. The Asian Pacific Journal of Cancer Prevention 2010 11 933 937
86. Boyle P., Boniol M., Koechlin A., Robertson C., Valentini F., Coppens K., Fairley L. L., Boniol M., Zheng T., Zhang Y., Pasterk M., Smans M., Curado M. P., Mullie P., Gandini S., Bota M., Bolli G. B., Rosenstock J., Autier P., Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 2012 51 2 85 94 10.1038/bjc.2012.414
87. Carpenter D. O., Environmental contaminants as risk factors for developing diabetes. Reviews on Environmental Health 2008 23 1 59 74 (Pubitemid 351644508)
88. Huang J. T., Welch J. S., Ricote M., Binder C. J., Willson T. M., Kelly C., Witztum J. L., Funk C. D., Conrad D., Glass C. K., Interleukin-4-dependent production of PPAR- γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999 400 6742 378 382 2-s2.0-0033595261 10.1038/22572 (Pubitemid 29344205)
89. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ Cell 1998 93 2 229 240 2-s2.0-0032540325 10.1016/S0092-8674(00)81574-3 (Pubitemid 28180856)
90. Berger J., Bailey P., Biswas C., Cullinan C. A., Doebber T. W., Hayes N. S., Saperstein R., Smith R. G., Leibowitz M. D., Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor- γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996 137 10 4189 4195 2-s2.0-0029745382 10.1210/en.137.10.4189 (Pubitemid 26321865)
91. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). The Journal of Biological Chemistry 1995 270 22 12953 12956 2-s2.0-0029016829 10.1074/jbc.270.22.12953
92. Lambe K. G., Tugwood J. D., A human peroxisome-proliferator-activated receptor- γ is activated by inducers of adipogenesis, including thiazalidinedione drugs. European Journal of Biochemistry 1996 239 1 1 7 2-s2.0-0029977518 (Pubitemid 26228133)
93. Acton J. J. III, Black R. M., Jones A. B., Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorganic & Medicinal Chemistry Letters 2005 15 357 362 (Pubitemid 39647150)
94. Fair A. M., Dai Q., Shu X. O., Matthews C. E., Yu H., Jin F., Gao Y. T., Zheng W., Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detection and Prevention 2007 31 3 214 219 2-s2.0-34547852246 10.1016/j.cdp.2007.04.003 (Pubitemid 47248150)
95. Pisani P., Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry 2008 114 1 63 70 2-s2.0-47349117519 10.1080/13813450801954451 (Pubitemid 351998745)
96. Belfiore A., Genua M., Malaguarnera R., PPAR- γ agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Research 2009 2009 18 2-s2.0-68949128792 10.1155/2009/830501 830501
97. Järvinen H. Y., Thiazolidinediones. The New England Journal of Medicine 2004 351 11 1106 1118 10.1056/NEJMra041001 (Pubitemid 39167514)
98. Burstein H. J., Demetri G. D., Mueller E., Sarraf P., Spiegelman B. M., Winer E. P., Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research and Treatment 2003 79 3 391 397 2-s2.0-0037899628 10.1023/A:1024038127156 (Pubitemid 36750946)
99. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K., Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR γ ligand troglitazone. Pancreas 2002 24 1 1 7 2-s2.0-0036135985 10.1097/00006676-200201000-00001 (Pubitemid 34019653)
100. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995 10.1073/pnas.180329197
101. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A., Characteristics of the peroxisome proliferator activated receptor γ (PPAR γ) ligand induced apoptosis in colon cancer cells. Gut 2002 50 5 658 664 2-s2.0-0036117576 10.1136/gut.50.5.658 (Pubitemid 34407493)
102. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation. Nature 1998 391 6662 79 82 2-s2.0-0031886864 10.1038/34178 (Pubitemid 28079218)
103. Kintscher U., Lyon C. J., Law R. E., Angiotensin II, PPAR-gamma and atherosclerosis. Frontiers in Bioscience 2004 1 359 369 (Pubitemid 38925466)
104. Helbig G., Christopherson K. W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K. D., Broxmeyer H. E., Nakshatri H., NF- B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. The Journal of Biological Chemistry 2003 278 24 21631 21638 2-s2.0-0038498102 10.1074/jbc.M300609200 (Pubitemid 36792563)
105. Sung B., Park S., Yu B. P., Chung H. Y., Amelioration of age-related inflammation and oxidative stress by PPAR γ activator: suppression of NF- B by 2, 4-thiazolidinedione. Experimental Gerontology 2006 41 590 599 10.1016/j.exger.2006.04.005 (Pubitemid 43867228)
106. Sung B., Park S., Yu B. P., Chung H. Y., Modulation of PPAR in aging, inflammation, and calorie restriction. The Journals of Gerontology A 2004 59 10 B997 B1006 10.1093/gerona/59.10.B997
107. Houseknecht K. L., Cole B. M., Steele P. J., Peroxisome proliferator-activated receptor gamma (PPAR γ) and its ligands: a review. Domestic Animal Endocrinology 2002 22 1 1 23 2-s2.0-0036010783 10.1016/S0739-7240(01)00117-5 (Pubitemid 34438654)
108. Ricote M., Li A. C., Willson T. M., Kelly J., Glass C. K., The peroxisome proliferators activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998 391 79 82 10.1038/34178 (Pubitemid 28079218)
109. Kerppola T. K., Luk D., Curran T., Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Molecular and Cellular Biology 1993 13 3782 3791 (Pubitemid 23157315)
110. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S. C., Heyman R. A., Rose D. W., Glass C. K., Rosenfeld M. G., A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996 85 3 403 414 2-s2.0-0242587820 10.1016/S0092-8674(00)81118- 6 (Pubitemid 26160711)
111. Glass C. K., Rosenfeld M. G., The coregulator exchange in transcriptional functions of nuclear receptors. Genes & Development 2000 14 121 141 (Pubitemid 30070977)
112. Tyagi S., Gupta P., Saini A. S., Kaushal C., Sharma S., The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. Journal of Advanced Pharmaceutical Technology & Research 2011 2 4 236 240 10.4103/2231-4040.90879